Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma Abstract #431

Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels<30 mg/dl, insulin 150 microUI/ml, and C-peptide at upper normal limits. Endocrinologist prescribed prednisone, diazoxide and recombinant glucagon for hypoglicemic crisis, with little benefit. In March 2010, the patient was given radio-labelled Lu-177-OCTREOTATE treatment. After three cycles, hypoglicemic symptoms were still uncontrolled. CT scan showed stable disease.
Aim(s): Considering persistent hypoglycemic syndrome, Everolimus was introduced.
Materials and methods: Everolimus 10 mg daily was administered in combination with radiometabolic treatment.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Anna Ferrero

To read results and conclusion, please login ...

Further abstracts you may be interested in

#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Miss Valérie Bernard
#1390 Ectopic Malignant Insulinoma with Multiple Liver Metastases: A Case Report
Introduction: Malignant insulinoma arising from ectopic pancreas is very rare.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Liu Q, Luo J, Li C, Zhu Z H, ...
#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma
Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Maria Vittoria Davì
#1257 A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series
Introduction: Malignant insulinoma is traditionally considered extremely rare and its natural history variable.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. Run Yu
Authors: Yu R, Nissen N N, Hendifar A, Fan X, ...
#425 Successful Treatment with Everolimus of Functioning Liver Metastases From a Pancreatic Insulinoma
Introduction: Medical treatment of metastatic insulinoma is debated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Maria Chiara Zatelli